C0039062||Synaptic
C0080093||NMDA Receptor
C1514758||Activation
C1519751||Ubiquitination
C0597297||Degradation
C1453844||STriatal-Enriched protein tyrosine Phosphatase 61 kDa
C0080093||NMDA receptor
C0037083||signaling
C0027880||synaptic plasticity
C0023185||learning
C0025260||memory
C0080093||NMDAR
C0037083||signaling
C0027765||neurological disorders
C0036341||schizophrenia
C0036341||schizophrenia
C1453844||STriatal-Enriched protein tyrosine Phosphatase 61 kDa
C1453844||STriatal-Enriched protein tyrosine Phosphatase 61 kDa
C0086418||human
C0036341||schizophrenia
C0004398||postmortem
C0007776||cortical
C1533734||administration
C0040284||cultures
C0025929||mice
C1514758||activation
C0039062||synaptic
C0080093||NMDAR
C0005372||bicuculline
C1880218||D-serine
C1519751||ubiquitination
C0597297||proteasomal degradation
C1447230||STriatal-Enriched protein tyrosine Phosphatase 61 kDa
C0061465||GluN1
C1099474||GluN2B receptors
C0005372||bicuculline
C1880218||D-serine
C0087111||treatments
C0521654||motor
C0009241||cognitive deficits
C0813872||MK-801
C0025929||mice
C1447230||STriatal-Enriched protein tyrosine Phosphatase 61 kDa
C0025929||mouse
C0016733||frontal cortex
C1447230||STriatal-Enriched protein tyrosine Phosphatase 61 kDa
C1527144||therapeutic effects
C1880218||D-serine